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ABSTRACT
ver the last decade the European Union (EU) has been coordinating actions addressing various aspects of rare diseases 
and has funded several cross-border research projects. Recently the EU has initiated the biggest rare disease interna-
tional collaborative effort by launching the International Rare Diseases Research Consortium (IRDiRC). 
RARE-Bestpractices is one of the more than 100 collaborative research projects on rare diseases funded under the Seventh 
Framework Programme for Research and Technological Development (FP7/2007-2013) [1]. 
As a wide, open and inclusive network, RARE-Bestpractices will build on the knowledge of the experts in rare disease 
RESEARCHAREAANDEXPERTSINGUIDELINEDEVELOPMENTANDHEALTHTECHNOLOGYASSESSMENTAREABROUGHTTOGETHERFORTHElRSTTIME
from academic institutions, agencies, organizations, patient advocacy groups, governmental bodies.
The project aims at building a platform to collect and exchange information on best practices for the management of rare 
DISEASESTOIDENTIFYRELEVANTRESEARCHNEEDSTOPROMOTETHEDEVELOPMENTOFHIGHQUALITYGUIDELINESANDTOCONTRIBUTEINMAKING
PATIENTSHEALTHPROFESSIONALSANDPOLICYMAKERShINFORMEDGUIDELINEUSERSv"ESIDES2!2%"ESTPRACTICESWILLINTENDTODElNE
the extent to which conclusions from cost-effectiveness analyses for pharmaceuticals are accounted for and implemented in 
guidelines across a range of countries.
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BACKGROUND 
Rare diseases are characterized by a low prevalence in the population although they are not actually rare since 
in aggregate approximately afflict millions of people of all ages in European countries and globally. In addition they 
are extremely diverse, as regard origin, severity and organ involved, with a high phenotypic variability within the same 
disease [2-3].
$ESPITERAREDISEASESAREHIGHLYDIVERSETHEOBSTACLESENCOUNTEREDBYALLCOUNTRIESINDELIVERINGTHEBESTQUALITYOF
evidence based care and treatment  to the patients affected are common. These obstacles include difficulties in attract-
ing funding and commitment for basic and clinical research and in translating basic science discoveries into appropriate 
clinical studies that will affect health care practice and health care systems [4-5]. In addition knowledge creation has 
suffered from a disease-specific approach and a lack of coordination of research initiatives.
To respond to these challenges the European Union has promoted actions to improve research and health services 
for rare disease patients in European member states [6-7-8-9-10]. In essence these actions has  supported innovative 
strategies to combine effort in sharing resources and infrastructures and making an efficient use of the knowledge avail-
able on rare diseases.
THE PROJECT 
RARE-Bestpractices project intends to respond to the need of what has been defined a “rare diseases knowledge 
common” [11] by developing a comprehensive system of publicly-accessible resources to facilitating communication 
and cooperation in the field of guidelines development, health technology assessment activities, and horizon scanning 
procedures.
RARE-Bestpractices addresses critical international challenges, such as the appropriate ways for timely translating 
CLINICALRESEARCHRESULTSINTOBENEFITSFORRAREDISEASEPATIENTSBYOFFERINGHIGHQUALITYINFORMATIONTOHEALTHPROFESSION-
als, to patients and their families. It also aims at promoting and supporting a consistent level of healthcare services in 
European countries.
The project is funded by the Seventh Framework Programme (FP7/2007-2013) of the European Union and will 
last four years (2013-2016). The National Centre for Rare Diseases (CNMR) of the Istituto Superiore di Sanità acts as a 
COORDINATORBRINGINGTOGETHERATEAMOFHIGHLYQUALIlEDEXPERTSINTHEAREAOFRAREDISEASEMANAGEMENTANDEPIDEMIOL-
ogy,  guidelines, systematic reviews, health technology assessments, horizon scanning, and health policies coming from 
9 countries and 15 organizations across Europe 
(Table 1). The consortium participants are assisted 
in their work by an external Advisory Board which 
is composed of experts from major organizations 
INTHElELDOFRAREDISEASESANDGUIDELINEDEVELOP-
ment. 
Specific project objectives are the fol-
lowings:
s REACH CONSENSUS ON THE METHODOLOGY TO
develop guidelines on rare diseases
sBUILDACOMPREHENSIVEPUBLICDATABASEOF
trustworthy guidelines to help professionals, pa-
tients, policy makers with the best and most up 
to date information on rare diseases
sBUILDACOMPREHENSIVEPUBLICDATABASEOF
research recommendations to identify and priori-
tize rare disease research needs
s DEFINE TO WHAT EXTENT CONCLUSIONS FROM
cost-effectiveness analyses for pharmaceuticals 
are accounted for and implemented in best prac-
tice guidelines across a range of countries
s SET UP TRAINING ACTIVITIES TARGETED AT KEY
stakeholders to spread expertise and knowledge 
in the field of  guidelines on rare diseases
s SUPPORT )2$I2# )NTERNATIONAL 2ARE
Diseases Research Consortium, www.irdirc.eu) 
activities as regards both the translation of re-
search results into patient oriented strategies and 
Table 1. Project participants
Italy Istituto Superiore di Sanità (Coordinator)
Consiglio Nazionale delle Ricerche 
!SSOCIAZIONEPERLA2ICERCASULL%FlCACIADELL
Assistenza Sanitaria Centro Cochrane Italiano 
Belgium The European Academy of Paediatrics
Bulgaria Bulgarian Association for Promotion of Educa-
tion and Science
France EURORDIS, European Organisation for Rare 
Diseases
Germany University of Freiburg
Spain Fundación Canaria de Investigación y Salud 
Institute of Rare Diseases Research,
Instituto de Salud Carlos III
Sweden Karolinska Institutet
The Netherlands Universiteit Maastricht
United Kingdom Healthcare Improvement Scotland 
Jamarau 
London School of Economics and Political 
Science 
University of Newcastle Upon Tyne
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the identification of research needs.
WORK PLAN 
The project has been organized into eight work packages (WP) to allow an efficient coordination of the project 
activities. 
7070AND70INCLUDETHECORERESEARCHACTIVITIES4HEYARERESPONSIBLEFORSETTINGTHEQUALITYSTANDARDSFOR
the development of rare disease guidelines (WP3), for collecting existing guidelines and research recommendations on 
rare diseases (WP4), for evaluating orphan drug appraisals in a range of countries to map out existing processes and best 
practices (WP5). 
The external communication of the project results and the interaction with other projects/networks/organizations 
are managed by WP6, which is also responsible for the publication of a periodic science journal. A dedicated WP (WP 
7) is working to establish collaboration with the IRDiRC.
WP2 is in charge of designing a flexible technical infrastructure  which includes the project web site (www.rarebe-
stpractices.eu), two databases (populated by WP4), and the web community, to support the project activities and the 
interaction among consortium participants and external stakeholders.
The transversal WP1 (coordination) and WP8 (management) deal with ensuring a smooth execution of project ac-
tivities. WP1 is also responsible for the organization of the training courses. 
EXPECTED RESULTS 
! TRANSPARENT AND RIGOROUSMETHODOLOGY FOR THE DEVELOPMENT OF GUIDELINES ON RARE DISEASESWILL BE DElNED4WO
BRAINSTORMINGWORKSHOPSHAVEBEEN FORESEEN IN2OMEAND&REIBURG	WITH THEAIMOF IDENTIFYING ISSUES SPECIlC TO THE
development of recommendations for rare diseases and exploring how GRADE1 meets such issues. GRADE is a widely 
adopted approach to synthesizing and presenting evidence, to grading evidence and to making recommendations in health 
care. A further workshop will be organized to discuss on aspects of the guideline production process not considered by 
'2!$%)NADDITIONTOTHECONSORTIUMPARTICIPANTSPATIENTREPRESENTATIVESINVITEDEXPERTSINTHElELDANDEXTERNALADVI-
sors (e.g. the GRADE working group) are particularly involved in the process. The agreed methodology will be applied and 
tested by developing a real guideline. Any criticisms will be discussed among partners to improve the methodology.
On the basis of the agreed methodology, training activities will be organised to promote the development of high 
QUALITYGUIDELINESFORRAREDISEASESANDTHEIRUSEACROSS%UROPE3UCHINITIATIVESWILLBETARGETEDTOKEYSTAKEHOLDERS
primarily guidelines developers of Centres of Expertise and European Reference Networks. A plan will be discussed 
among partners to define aspects such as training format, skills and expertise to involve in running the courses (to be 
sought within and outside the network), and methods to assess the training value. 
&INDINGUPDATEDHIGHQUALITYGUIDELINESONRAREDISEASESISNOTSIMPLE#URRENTLYEXISTINGDATABASESANDWEBSITES
often include very heterogeneous documents. This is the consideration leading to the idea of creating a database which 
WILLMAKEACCESSIBLEACOLLECTIONOFRAREDISEASEGUIDELINESINCLUDINGANEVALUATIONJUDGMENTABOUTQUALITYINDEVELOP-
ment for each item. The aim is to provide health professionals, patients and their families,  and policy makers with high 
QUALITYANDUPTODATEINFORMATIONABOUTTHEMANAGEMENTOFRAREDISEASES
!SECONDSPECIFICDATABASEWILLCOLLECTRAREDISEASERESEARCHRECOMMENDATIONSIEUNANSWEREDRESEARCHQUESTIONS
that might emerge during the guideline or health technology assessment  development. Reflecting the research needs, 
they may be crucial in orienting the research agenda. Mechanisms to prioritize research recommendations will be iden-
tified and applied within the database to promote future research. Partners and key stakeholders will be involved to 
inform the collection development criteria for both databases trough a preliminary information needs analysis. 
In the mainstream debate about the appropriate processes to determine the value for money of new technologies, 
ORPHANDRUGASSESSMENTREQUIRESPARTICULARCONSIDERATIONS FORANUMBEROF REASONS INCLUDINGHIGHPRICE LIMITEDEVI-
dence available, no therapeutic options. 
RARE-Bestpractices will map out the current processes for the appraisal of orphan drugs to investigate divergences 
INCOVERAGEDECISIONSWHICHRESULTINUNEQUALACCESSTOTREATMENTSFORPATIENTSACROSSCOUNTRIES!SELECTIONOFORPHAN
drugs approved between 2006 and 2012 in a number of European countries will be identified to understand how ap-
praisals were conducted, the critical factors leading to positive and negative recommendations, and how do assessments 
feed into clinical practice guidelines. Best practices based on the evidence collected will be identified across member 
states by benchmarking with individual practices on a per-case basis.
Finally, RARE-Bestpractices will enhance interaction among stakeholders through the publication of a new inter-
national open access, online, peer-reviewed journal focussing on important aspects of public health, health policy and 
clinical research on rare diseases. The journal RARE DISEASES AND ORPHAN DRUGS. An International journal of 
public health (RARE Journal, www.rarejournal.org) will be published three times per year, with no publishing fees for 
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READERSANDAUTHORSANDWILLMAKEAVAILABLEHIGHQUALITYARTICLESFROMEPIDEMIOLOGYPUBLICHEALTHHEALTHECONOMICS
social sciences, ethics and law. 
DISCUSSION
RARE-Bestpractices will contribute to establishing a wide community of stakeholders interested in producing, 
ACQUIRINGANDSHARINGKNOWLEDGEANDRELIABLEINFORMATIONONTHEMANAGEMENTOFRAREDISEASES
4HEPARTNERSHIPINTENDSTOOFFERARESPONSETOTHECHALLENGESOFIMPROVINGQUALITYANDCONSISTENCYOFBESTPRACTICES
for rare diseases, complying with the European Union directive which encourages European member states to provide 
HIGHQUALITYANDQUANTITATIVELYADEQUATEHEALTHCARETOCITIZENSASWELLASTOPRODUCEhGOODPRACTICESGUIDELINESv;=
The benefits of well developed guidelines in supporting health related decision are widely recognized [12]. They 
are particular helpful for the rare diseases community, for which identifying and disseminating the most scientifically 
SOUNDHEALTHCAREPRACTICESREQUIRESMOREEFFORTTHANFORCOMMONCONDITIONS
RARE-Bestpractices will address this matter by ensuring that patients and their families, health professionals, 
policy makers have access to “trustworthy” guidelines on rare diseases.
This will be provided by developing  a methodology which explores issues specific for rare diseases, assessing the 
use of GRADE approach [13] in creating guidelines for rare diseases and drawing on existing initiatives in the field of 
“standards for guidelines” [12, 14 - 16].
In addition, a comprehensive information system including resources to facilitate communication and cooperation 
in the field of guidelines on rare diseases (collection of guidelines, training tools, etc.) will be made publicly available.
4HROUGHTHESEINITIATIVESTHE2!2%"ESTPRACTICESCONSORTIUMINTENDSTOPROMOTETHEDEVELOPMENTOFHIGHQUALITY
guidelines and to contribute in making patients, health professionals and policy makers “an informed guideline user”. 
As a wide, open and inclusive network, RARE-Bestpractices will build on the knowledge of the experts in rare 
diseases research area and experts in guidelines and health technology assessment area, brought together, for the first 
time, from academic institutions, agencies, organizations, patient representatives, governmental bodies. This will maxi-
mize the dissemination of the outputs of the project ensuring uptake of its innovative findings by the rare disease com-
munity, including rare disease national plans, Centres of Expertise  and European Reference Networks in compliance 
with European Union legislation.
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